首页 | 本学科首页   官方微博 | 高级检索  
     

双歧杆菌四联活菌片用于细菌性医院获得性肺炎治疗的随机单盲临床研究
引用本文:李思聪 王青青 陶永康 李超. 双歧杆菌四联活菌片用于细菌性医院获得性肺炎治疗的随机单盲临床研究[J]. 中国抗生素杂志, 2020, 45(7): 727-S1
作者姓名:李思聪 王青青 陶永康 李超
摘    要:目的 评价双歧杆菌四联活菌片治疗细菌性医院获得性肺炎的临床疗效。方法 将382名细菌性医院获得性肺炎患者随机分为2组,191例纳入对照组的患者接受常规抗菌药物治疗,另外191例治疗组患者在此基础上联合双歧杆菌四联活菌片治疗,比较C反应蛋白、白细胞计数、降钙素原、临床肺炎评分CPSI等感染相关指标,比较两组抗菌药物使用天数、住院天数、需要机械通气人数以及临床有效率。结果 治疗后,试验组与对照组患者比较,白细胞计数(Z=-3.992, P<0.001)、C反应蛋白(Z=-2.634, P<0.01)、降钙素原(Z=-2.384, P<0.05)、临床肺部感染评分CPIS(Z=-2.655, P<0.01)。试验组患者住院时间(χ2=-2.801, P<0.001),抗菌药物使用天数(χ2=-6.799, P<0.01),需要机械通气的人数(χ2=5.793, P<0.05)均少于对照组。结论 双歧杆菌四联活菌片联合常规抗菌药物治疗医院获得性肺炎的临床疗效优于单纯应用抗菌药物,值得临床推广应用。

关 键 词:医院获得性肺炎  双歧杆菌四联活菌片  抗菌药物  肠道菌群  耐药  

Randomized single-blind clinical study of Bifidobacterium tetrabacterial tablets for the treatment of hospital-acquired bacterial pneumonia#br#
Li Si-cong,Wang Qing-qing,Tao Yong-kang and Li Chao. Randomized single-blind clinical study of Bifidobacterium tetrabacterial tablets for the treatment of hospital-acquired bacterial pneumonia#br#[J]. Chinese Journal of Antibiotics, 2020, 45(7): 727-S1
Authors:Li Si-cong  Wang Qing-qing  Tao Yong-kang  Li Chao
Abstract:Objective To evaluate the clinical efficacy of Bifidobacterium tetrad viable tablets for the treatment of hospital-acquired bacterial pneumonia. Methods 382 patients with hospital-acquired bacterial pneumonia were randomly divided into two groups. 191 patients in the control group were treated with routine antibiotics, and the other 191 patients in the treatment group were treated with Bifidobacterium tetrad viable tablets on this basis. Inflammation-related indicators such as C-reactive protein (CRP), white blood cell count (WBC), procalcitonin (PCT), and clinical pneumonia infection score (CPIS) were compared. The days of antibiotic use, hospitalization, and the number of people requiring mechanical ventilation and prognosis were compared between the two groups. Results After treatment, the WBC (Z=-3.992, P<0.001), CRP (Z=-2.634, P<0.01), PCT (Z=-2.384, P< 0.05), CPIS (Z=-2.655, P< 0.01) of the test group was lower than the control group. The total length of hospitalization (χ2=-2.801, P<0.001), days of antibiotic use (χ2=-6.799, P< 0.01), and the number of people requiring mechanical ventilation (χ2= 5.793, P< 0.05) of the test group were less than the control group. The clinical efficacy was compared (χ2=4.745, P<0.05). Conclusion The clinical efficacy of Bifidobacterium tetrabacterial tablets combined with conventional antibiotics in the treatment of hospital acquired pneumonia is better than that of antibiotics alone, which is worthy of clinical application.
Keywords:Hospital acquired pneumonia  Tetralogy of viable Bifidobacterium tablets  Antibiotic  Intestinal flora  Drug resistance  
点击此处可从《中国抗生素杂志》浏览原始摘要信息
点击此处可从《中国抗生素杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号